ISPOR - PBI31 A Reimbursement LAG Analysis to Understand How EARLY WAS CAR T-Cell Therapy Reimbursed across Europe

PBI31 A Reimbursement LAG Analysis to Understand How EARLY WAS CAR T-Cell Therapy Reimbursed across Europe

Abstract

Authors

P. Borga

Full Text Cite This Article

Back to Volume 23, Supplemental S2

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now